The number of U.S. women with breast cancer that has spread elsewhere in the body by the time of diagnosis increased ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- More breast cancers are being detected later in women, giving the tumors a chance ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

The number of women with late-stage, invasive breast cancer at the time of diagnosis increased significantly among U.S. women ...

About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Ninety percent of cancer deaths are due to the spread of cancer, not complications from the original tumor. Thus, for over 50 ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.